Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Recruiting · NCT04322617 · Registry updated 2024-06-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2024-06-04 | NCT04322617 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hunan Province Tumor Hospital | 27 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Yongchang Zhang | Changsha | China | 7 |